HER2 heterogeneity corresponds to tumors with both HER2-negative and HER2-positive areas, representing a minority of situations (up to 1% of the cases), with patients requiring at least 10% of HER2-positive areas in the BC to be elected for targeted therapy [7]. The gene discussed is ERBB2; the disease is breast cancer.